ConjuChem Biotechnologies has completed the enrollment of its Phase II trial with DAC:GRF in patients having lipodystrophy associated with HIV. DAC:GRF, a growth hormone therapeutic, is a compound employing the growth hormone-releasing factor peptide and is being evaluated in a once-weekly dosing regimen.
The study is a multicenter, randomized, double-blind, placebo-controlled trial in HIV-associated Lipodystrophy patients. The primary endpoint is the change in IGF-1 levels from baseline to week 12. Secondary endpoints include changes in visceral adipose tissue and subcutaneous adipose tissue (as measured by CT scan), lean body mass, body composition (as measured by DEXA scan), weight and body image assessment.
